Their biomarker potential and role in MS pathogenesis are reflected by previous studies indicating their presence in the CSF proteome of patients with RRMS, and upregulation of TIMP-1 and B2M in the CSF proteome of RRMS compared to controls [65–69]. Here, B2M is linked to myeloid sarcoma.